Autoimmune primary adrenal insufficiency -current diagnostic approaches and future perspectives

Front Endocrinol (Lausanne). 2023 Nov 10:14:1285901. doi: 10.3389/fendo.2023.1285901. eCollection 2023.

Abstract

The adrenal glands are small endocrine glands located on top of each kidney, producing hormones regulating important functions in our body like metabolism and stress. There are several underlying causes for adrenal insufficiency, where an autoimmune attack by the immune system is the most common cause. A number of genes are known to confer early onset adrenal disease in monogenic inheritance patterns, usually genetic encoding enzymes of adrenal steroidogenesis. Autoimmune primary adrenal insufficiency is usually a polygenic disease where our information recently has increased due to genome association studies. In this review, we go through the physiology of the adrenals before explaining the different reasons for adrenal insufficiency with a particular focus on autoimmune primary adrenal insufficiency. We will give a clinical overview including diagnosis and current treatment, before giving an overview of the genetic causes including monogenetic reasons for adrenal insufficiency and the polygenic background and inheritance pattern in autoimmune adrenal insufficiency. We will then look at the autoimmune mechanisms underlying autoimmune adrenal insufficiency and how autoantibodies are important for diagnosis. We end with a discussion on how to move the field forward emphasizing on the clinical workup, early identification, and potential targeted treatment of autoimmune PAI.

Keywords: 21-hydroxylase autoantibodies; Addisons disease; Genetic causes of PAI; glucococorticoids; primary adrenal insufficiency (PAI).

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Addison Disease* / diagnosis
  • Addison Disease* / genetics
  • Adrenal Glands
  • Adrenal Insufficiency* / diagnosis
  • Adrenal Insufficiency* / genetics
  • Adrenal Insufficiency* / therapy
  • Autoantibodies
  • Humans
  • Kidney

Substances

  • Autoantibodies

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. BO and IK are supported by grant from the Novo Nordic foundation (103302), AW and BO are supported by the Regional Health Authorities of Western Norway. The funders provide salary for the authors and do not influence the direction of our research.